MedTrace Logo

RE104 Safety and Efficacy Study in Postpartum Depression

NCT06342310 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-control.

Conditions

Interventions

DRUG

RE104 for Injection

Single, subcutaneous dose of RE104 for Injection

Sponsors & Collaborators

  • Reunion Neuroscience Inc

    lead INDUSTRY

Principal Investigators

  • Jasna Hocevar-Trnka, M.D. · Reunion Neuroscience Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-14
Primary Completion
2025-05-22
Completion
2025-06-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06342310 on ClinicalTrials.gov